Reuters logo
BRIEF-Teva's Fremanezumab meets all primary & secondary endpoints in phase III study in episodic migraine prevention
June 7, 2017 / 12:15 PM / 4 months ago

BRIEF-Teva's Fremanezumab meets all primary & secondary endpoints in phase III study in episodic migraine prevention

June 7 (Reuters) - Teva Pharmaceutical Industries Ltd

* Teva’s fremanezumab meets all primary & secondary endpoints across both monthly and quarterly dosing regimens in phase iii study in episodic migraine prevention

* Teva - in em study, patients treated with monthly, quarterly fremanezumab experienced significant improvements in all endpoints, 12 pre-specified analyses

* Teva Pharmaceutical - plans to submit a biologics license application to u.s. Fda for fremanezumab later this year in both episodic and chronic migraine Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below